Literature DB >> 12641877

Hemodynamic cardiovascular risk factors in chronic kidney disease: what are the effects of intervention?

Lawrence P McMahon1.   

Abstract

Left ventricular (LV) volume and pressure overload occur frequently in chronic kidney disease (CKD). Anemia is a risk factor for left ventricular hypertrophy (LVH) and dilatation, heart failure, and death. Normalization of hemoglobin with erythropoietin may prevent LVH and dilatation in CKD, but in patients in later phases of their cardiac disease, this intervention is not of benefit. Increased vascular volume causes hypertension, which in turn causes LVH, cardiac failure, and ischemic heart disease (IHD). Manifestations of arteriosclerosis are associated with adverse cardiac outcomes, and angiotensin converting enzyme (ACE) inhibitors may improve LVH and markers of arteriosclerosis. Aortic stenosis in dialysis patients occurs infrequently, but may deteriorate rapidly. The hemodialysis milieu is the quintessential model of LV overload cardiomyopathy.

Entities:  

Mesh:

Year:  2003        PMID: 12641877     DOI: 10.1046/j.1525-139x.2003.16029.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  3 in total

Review 1.  Modulation of vitamin D signaling is a potential therapeutic target to lower cardiovascular risk in chronic kidney disease.

Authors:  Peng Hu; Bo Hu; Jing Wang; Ling Lu; Yuan Han Qin
Journal:  Med Sci Monit       Date:  2011-06

2.  Hemodialysis and hemodiafiltration differently modulate left ventricular diastolic function.

Authors:  Arpád Czifra; Alida Páll; Julianna Kulcsár; Kitti Barta; Attila Kertész; György Paragh; István Lőrincz; Zoltán Jenei; Anupam Agarwal; Abolfazl Zarjou; József Balla; Zoltán Szabó
Journal:  BMC Nephrol       Date:  2013-04-02       Impact factor: 2.388

Review 3.  Hypertension in the metabolic syndrome and diabetes: pathogenesis, clinical studies, and treatment.

Authors:  Joseph L Izzo
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Nov-Dec       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.